We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
With an eye toward rare-disease research, the Biotechnology Industry Organization and a Duchenne patient advocacy group are joining forces to help drugmakers design clinical studies with patient input. Read More
A law firm that represents drugmakers is urging the FDA to rethink its stance on granting meetings with senior FDA officials, saying the agency’s policy can imperil drug research. Read More
Real-world research offers the potential to better understand a medicine’s value in a clinical setting, but to fully harness its potential, drugmakers will need to restructure the way they think. Read More